Food and Drug Administration (FDA) Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Guidelines for the Management of Patients with Orofacial Pain and Temporomandibular Disorders
The management of patients with orofacial pain and temporomandibular disorders is challenging. Recognizing the opportunity to advance patient care, in 2019 the National Academies of Science, Engineering, and Medicine (NASEM) convened representatives from the Food and Drug Administration, Medical Device Epidemiology Network (MDEpiNet), patient advocacy groups, oral and maxillofacial surgeons, and orofacial pain experts to identify specific steps to improve care for patients. In response, the American Association of Oral and Maxillofacial Surgeons (AAOMS) created the Special Committee on Temporomandibular Joint Care (SCTMJC)...
Source: Journal of Oral and Maxillofacial Surgery - March 25, 2024 Category: ENT & OMF Authors: Gary F. Bouloux, Joli Chou, Vince DiFabio, Greg Ness, Daniel Perez, Louis Mercuri, William Chung, Gary D. Klasser, Steven D. Bender, Steven Kraus, Charles A. Crago Tags: Review Article Source Type: research

Stress resistant rpsU variants of Listeria monocytogenes can become underrepresented due to enrichment bias
This study investigated whether these switches in phenotypes could result in a bias in strain detection when standard enrichment-based procedures are applied to a variety of strains. Detailed growth kinetics analysis of L. monocytogenes strains were performed, including the LO28 wild type (WT) and rpsU variants V14 and V15, during two commonly used enrichment-based procedures described in the ISO 11290-1:2017 and the U.S. Food and Drug Administration Bacteriological Analytical Manual (BAM). WT had a higher growth rate than the variants during the enrichment processes. Co-culture growth kinetics predictions for WT and rpsU ...
Source: International Journal of Food Microbiology - March 24, 2024 Category: Food Science Authors: Xuchuan Ma Jingjie Chen Marcel H Zwietering Tjakko Abee Heidy M W Den Besten Source Type: research

GSE261921 Synergistic Activity of Adefovir Dipivoxil and Venetoclax to Target the Bioenergetic Metabolism of Acute Myeloid Leukemia
Contributors : Bin Zhang ; Min-Hsuan ChenSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensThe overall outcome of patients with acute myeloid leukemia (AML) remains poor and more effective strategies are urgently needed. Adefovir dipivoxil (ADV) is an oral prodrug of the nucleotide analogue adefovir that inhibits viral DNA polymerase and is a Food and Drug Administration (FDA)-approved drug for the treatment of hepatitis B virus. Preliminary evidence of the anti-leukemic activity of ADV was recently reported in a patient with acute promyelocytic leukemia. Herein we report on the anti-...
Source: GEO: Gene Expression Omnibus - March 24, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research

Synergistic therapeutics: Co-targeting histone deacetylases and ribonucleotide reductase for enhanced cancer treatment
Eur J Med Chem. 2024 Mar 16;269:116324. doi: 10.1016/j.ejmech.2024.116324. Online ahead of print.ABSTRACTThe development of cancer is influenced by several variables, including altered protein expression, and signaling pathways. Cancers are inherently heterogeneous and exhibit genetic and epigenetic aberrations; therefore, developing therapies that act on numerous biological targets is encouraged. To achieve this, two approaches are employed: combination therapy and dual/multiple targeting chemotherapeutics. Two enzymes, histone deacetylases (HDACs) and ribonucleotide reductase (RR), are crucial for several biological func...
Source: European Journal of Medicinal Chemistry - March 23, 2024 Category: Chemistry Authors: Manasa Gangadhar Shetty Padmini Pai Mythili Padavu Kapaettu Satyamoorthy Babitha Kampa Sundara Source Type: research

Comprehensive review of statin-intolerance and the practical application of Bempedoic Acid
J Cardiol. 2024 Mar 21:S0914-5087(24)00045-5. doi: 10.1016/j.jjcc.2024.03.006. Online ahead of print.ABSTRACTStatin-intolerance (SI) has prevalence between 8.0 % and 10 %, and muscular complaints are the most common reason for discontinuation. Bempedoic acid (BA), an ATP citrate lyase inhibitor, decreases hepatic generation of cholesterol, upregulates low-density lipoprotein (LDL) receptor expression in the liver, and eventually clears circulating LDL-cholesterol from the blood. Multiple randomized clinical trials studying BA demonstrate a reduction in LDL levels by 17-28 % in SI. The CLEAR OUTCOME trial established signif...
Source: Journal of Cardiology - March 23, 2024 Category: Cardiology Authors: Siva Naga S Yarrarapu Amandeep Goyal Vikramaditya Samala Venkata Viraj Panchal Barath Prashanth Sivasubramanian Doantrang T Du Roopesh Sai Jakulla Hema Pamulapati Mazhar A Afaq Steven Owens Tarun Dalia Source Type: research

Pharmacology and pharmacokinetics of tazemetostat
AbstractTazemetostat, a novel oral selective inhibitor of enhancer of zeste homolog 2 (EZH2), was approved by the Food and Drug Administration (FDA) in 2020 for use in patients with advanced epithelioid sarcoma or relapsed/refractory (R/R) EZH2-mutated follicular lymphoma. These indications were approved by the FDA trough accelerated approval based on objective response rate and duration of response that resulted from phase 2 clinical trials. Tazemetostat competes with S-adenosylmethionine (SAM) cofactor to inhibit EZH2, reducing the levels of trimethylated lysine 27 of histone 3 (H3K27me3), considered as pharmacodynamic m...
Source: Cancer Chemotherapy and Pharmacology - March 23, 2024 Category: Cancer & Oncology Source Type: research